clinical trial Archive — Page 15 of 16
-
January 15, 2015
New drugs approved to fight idiopathic pulmonary fibrosis
The Vanderbilt Idiopathic Pulmonary Fibrosis Center played a key role in testing the first two drugs approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF). -
August 7, 2014
Study tracks new end-stage renal disease therapy
Researchers in Vanderbilt’s Division of Nephrology conducted a Phase 3 clinical trial to test the safety and efficacy of a new drug to treat patients with end-stage renal disease. -
April 3, 2014
DBS for Parkinson’s trial moves to next level
A long-term Vanderbilt University Medical Center study of deep brain stimulation (DBS) in early-stage Parkinson’s disease has received approval from the Food and Drug Administration (FDA) to continue in a pivotal, phase III, large-scale safety and efficacy trial. -
November 14, 2013
Heart Institute studying absorbable coronary stent
Vanderbilt Heart and Vascular Institute is participating in a clinical trial to evaluate a medical device for the treatment of coronary artery disease. -
October 29, 2013
Vanderbilt to study use of plasma on LifeFlight
Vanderbilt University Medical Center will participate in a national trial to see if outcomes for critically injured patients with uncontrolled bleeding can be improved by administering plasma to these patients while in flight to the hospital. -
October 24, 2013
Glucose control study gives patients new path to health
The IDIOM study is designed to compare how a diet with moderate caloric restriction, alone or with long-acting insulin, affects areas of the brain’s dopamine system that are involved in food intake, reward and the sense of pleasure people get from eating. -
September 12, 2013
VU tracking drug’s ability to prevent type 1 diabetes
Vanderbilt’s Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.